Debates continue over Gilead and Arcus' TIGIT combo despite updated data at ASCO23.
Gilead and Arcus presented updated data on their experimental cancer immunotherapy combo, which showed lower progression-free survival rates than the previous update. The anti-TIGIT/anti-PD-L1 combo, positioned as a first-line treatment for non-small cell lung cancer, recorded data that drew mixed reactions. The latest analysis, presented at ASCO, included only a handful more patients than the previous update, but PFS rates fell.
